

Case 18

48 year old female.


Core biopsy of a right breast lump.



















































































Diagnosis

Core biopsy, right breast lump ~

Papillary ductal carcinoma in situ, low to intermediate nuclear grade, without necrosis or calcifications.

ER strongly positive, PR weakly positive.







Papillary ductal carcinoma in situ

- Papillary intraductal carcinoma.
- Non-invasive malignant lesion with papillary architecture arising within the ducts.
- In contrast to an intraductal papilloma with DCIS, papillary DCIS is regarded as a de novo in situ malignant papillary process without a morphologically recognisable benign papilloma in its background.
- It is uncommon in its pure form and is often seen in conjunction with other morphological patterns of DCIS.



International Academy of Pathology

Wilm's tumour protein

- Wilm's tumour protein ~ encoded by the WT1 gene on chromosome 11p.
- Transcription factor comprising 4 zinc finger motifs at the C-terminus, proline/glutamine-rich DNA binding domain at the N-terminus.
- Role in the normal development of the urogenital system.
- Tumour suppressor gene.
- WT1 gene is mutated in a subset of Wilm's tumours.





Wilm's tumour protein

- A less frequently used myoepithelial marker due to low sensitivity.
- Other myoepithelial markers ~
 - p63, SMMHC, calponin, SMA, S100, CD10, maspin, P-cadherin.
- Marks endothelial cells as well.
- Immunohistochemistry ~
 - Nuclear localization transcriptional regulation in the nucleus.
 - Cytoplasmic localization transcriptional regulation in the cytoplasm.

Nakatsuka et al. Modern Pathology (2006) 19, 804–814







WT1 in breast myoepithelial cells

- Cytoplasmic reactivity.
- Few studies describing the use of WT1 in breast myoepithelial cells.







Cancer Biomark. 2009;5(3):109-16. doi: 10.3233/CBM-2009-0595.

Dual usages of single Wilms' tumor 1 immunohistochemistry in evaluation of breast tumors: a preliminary study of 30 cases.

Li JH(1), Man YG. (1)Center of Anatomy and Functional Morphology, Mount Sinai School of Medicine, New York, NY, USA.

Our previous studies revealed that Wilms' tumor 1 (WT-1) protein was highly expressed in breast myoepithelial (ME) and endothelial cells. As the human breast tissue is rich in ME cells and blood vessels, our current study intended to assess whether WT-1 immunohistochemistry may have dual usages in evaluation of the ME cells and micro-vessel density. Consecutive sections were prepared from breast tumors with co-existing normal, hyperplastic, and neoplastic components. Consecutive sections were immunostained for WT-1 and a panel of ME and endothelial cell markers. From each case, 4-5 randomly selected duct clusters were photographed, and the percentages of positive cells for these molecules were compared. Similar to ME cell marker CD10 and smooth muscle actin (SMA), WT-1 expression was preferentially seen in ME cells, and over 90% of WT-1 positive ME cells were immunoreactive to CD10 and SMA. Distinct WT-1 expression was also seen in endothelial cells, and over 90% of WT-1 positive endothelial cells were positive for blood vessel specific markers. With tumor progression, the percentage and intensity of WT-1 positivity decreased in ME cells, whereas increased in endothelial cells. These finding suggest that WT-1 immunohistochemistry may be used to assess both the ME cells and micro-vessel density.

International Journal of Biological Sciences

2009; 5(1):82-96

PMCID: PMC314436

© Ivyspring International Publisher. All rights reserved

Research Paper

Aberrant p63 and WT-1 expression in myoepithelial cells of pregnancy-associated breast cancer: implications for tumor aggressiveness and invasiveness

Zheli Xu¹, Wan Wang¹, Chu-Xia Deng², Yan-gao Man³ ™



Breast Cancer Res. 2003; 5(5): R151–R156.

Published online 2003 Jul 24. doi: 10.1186/bcr635

A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers

Roy R Zhang,¹ Yan-Gao Man,²⁰1 Russell Vang,¹ Jeffrey S Saenger,¹ Ross Barner,¹ Darren T Wheeler,¹ Chang Y Liang,¹
Tuyethoa N Vinh,¹ and Gary L Bratthauer¹

Author information ► Article notes ► Copyright and License information ►

WT1 used as a myoepithelial marker

WT1 immunoreactivity in breast carcinoma

- WT1 expression is reported in approximately 10% of carcinomas that show mixed micropapillary and mucinous morphology, mostly weak to moderate intensity.
- Not expressed in non-mucinous subtypes. *Mod Pathol. 2008 Oct;21(10):1217-23*







